<![CDATA[Breast Cancer Experts Preview Abstracts to Watch at the 2026 ESMO Breast Cancer Congress]]>

Advertisement Commentary|Articles|May 5, 2026 Breast Cancer Experts Preview Abstracts to Watch at the 2026 ESMO Breast Cancer Congress Author(s)Ashling Wahner Fact checked by: Chris Ryan, Kirsty Mackay Listen0:00 / 0:00 Experts in a range of breast cancer subtypes highlight research data being presented at the 2026 ESMO Breast Cancer Congress. Advertisement As we gear up for the 2026 European Society for Medical Oncology (ESMO) Breast Cancer Congress, taking place May 6 to 8, 2026, in Berlin, Germany, OncLive® asked leading breast oncologists to share the presentations and conversations at the top of their lists. We gathered exclusive insights from:Sarah Sammons, MD, associate director of the Metastatic Breast Cancer Program and a senior physician at Dana-Farber Cancer Institute, as well as an assistant professor of medicine at Harvard Medical School, both in Boston, MassachusettsPaolo Tarantino, MD, PhD, a clinical fellow at Dana-Farber Cancer InstituteSara M. Tolaney, MD, MPH, chief of the Division of Breast Oncology and associate director of the Susan F. Smith Center for Women’s Cancers and a senior physician at Dana-Farber Cancer Institute, as well as an associate professor of medicine at Harvard Medical School“I always love going to Berlin for ESMO Breast, because there are always so many interesting subanalyses and updates that sometimes affect practice or at least tell us how to treat patients better and what to prioritize,” Tarantino emphasized. “ESMO Breast 2026 has several interesting oral presentations, mini-oral presentations, and posters. Among these are some I'm very curious about. I cannot wait to go to Berlin and jump into the presentations and posters. If you will be in Berlin, feel free to reach out! One of the things I love most about ESMO Breast is that it always provides a small space where people can meet, discuss, and build collaborations.”Read on for a glance at studies you should keep an eye on, as well as how their results might propel the future of breast oncology.What data updates in HER2-positive early-stage breast cancer are important to note?LBA1 - Residual Cancer Burden (RCB) Following Neoadjuvant Treatment (NAT) With Trastuzumab Deruxtecan (T-DXd) Followed by Paclitaxel + Trastuzumab + Pertuzumab (THP) vs Dose-Dense Doxorubicin + Cyclophosphamide Followed by THP (ddAC-THP) in High-Risk HER2+ Early-Stage Breast Cancer (eBC)Presentation time: May 6, 2026, 4-4:10 PM Central CEST (Central European Summer Time)214O - Chemotherapy-Free, Pathological Complete Response (pCR)-Guided Strategy With Trastuzumab-Pertuzumab (HP) and T-DM1 in HER2+ Early Breast Cancer (EBC): PHERGain-2Presentation time: May 6, 2026, 4:10-4:20 PM CEST216RO - 5-Year Invasive Disease-Free Survival (iDFS) of the Strategy-Based, Randomized Phase II PHERGain Trial Evaluating Chemotherapy (CT) De-Escalation in HER2[+] Early Breast Cancer (EBC) Patients (pts)Presentation time: May 7, 2026, 8:30-8:35 AM CESTSammons: The [phase 3] DESTINY-Breast11 trial [NCT05113251] was a landmark study investigating the novel treatment regimen of fam-trastuzumab deruxtecan-nxki [T-DXd; Enhertu] followed by paclitaxel plus trastuzumab [Herceptin] and pertuzumab [Perjeta; THP] in HER2-positive early-stage breast cancer. We've already seen data from DESTINY-Breast11 showing that T-DXd followed by THP outperforms dose-dense doxorubicin and cyclophosphamide plus THP (ddAC-THP) in terms of pathologic complete response [pCR] rate.1 We'll see an update of the study regarding residual breast cancer burden [RCB] at [ESMO Breast 2026], and we await [potential] FDA approval in the coming months for this regimen.2Tolaney: Some of the data are covering updated analyses from prior presentations. We've seen data from DESTINY-Breast11, and we will see data that will evaluate RCB within that trial that will be interesting. We'll also see updated data from the [phase 2] PHERGain trial [NCT03161353] that investigated pre-operative trastuzumab plus pertuzumab. We'll also see data from the phase 2 PHERGain-2 trial [NCT04733118]. These 3 studies assess different perspectives of escalation of care in the preoperative setting, as well as what I would consider more de-escalation of preoperative treatment for patients with HER2-positive disease.Tarantino: PHERGain-2 is a trial testing a chemotherapy-free strategy as neoadjuvant treatment for HER2-positive breast cancer with selective trastuzumab/pertuzumab and ado-trastuzumab emtansine [Kadcyla] escalation in patients who require it, as well as the predictive ability of MRI to understand whether this can help tailor treatment in early-stage HER2-positive breast cancer. This trial is going to be extremely interesting. Then there is a subanalysis of a trial that [may change] practice: DESTINY-Breast11, which investigated T-DXd in the neoadjuvant setting, with or without sequential THP. Investigators will present the analysis of outcomes by RCB. This is intriguing and will tell us more about this regimen, which we expect may be approved over the coming months to manage early-stage HER2-positive breast cancer, [and may be] moving to other subtypes of disease, [including] the metastatic setting.Which clinical trials will provide insights into antibody-drug conjugate sequencing in metastatic breast cancer?422RO - A Phase 2 Study of Patritumab Deruxtecan (HER3-DXd) in Patients (pts) With Metastatic Breast Cancer (MBC)Presentation time: May 8, 2026, 9:00-9:05 AM CESTLBA4 - Efficacy and Safety of Gacituzumab Govitecan (SG) Plus Trastuzumab in Patients With HER2+ Metastatic Breast Cancer After Prior Trastuzumab Deruxtecan (T-DXd): Results From the Phase II SATEEN TrialPresentation time: May 8, 2026, 9:05-9:10 AM CESTSammons: In advanced HER2-positive breast cancer, we will see [data from the phase 2] SATEEN trial [NCT06100874], presented by Dr Tarantino and colleagues from Dana-Farber, evaluating sacituzumab govitecan-hziy [Trodelvy] plus trastuzumab following [prior treatment] with T-DXd. This is one of the first prospective studies looking at the sequencing of topoisomerase inhibitor antibody-drug conjugates [ADCs] one after the other to see whether there's any efficacy [when using] one topoisomerase inhibitor after another. That will be interesting.Tolaney: We'll see data on ADC sequencing from prospective trials. To date, we've only seen retrospective data from case series, but we will see data from the SATEEN trial investigating the combination of sacituzumab govitecan and trastuzumab in patients who've previously received T-DXd for metastatic HER2-positive breast cancer. We'll also see data [from a phase 2 trial (NCT04699630)] with HER3-DXd in patients who previously received T-DXd for metastatic HER2-positive breast cancer. That will be the first set of prospective studies that I'm aware of that evaluate sequential ADC use. That's been a long-anticipated question that needed to be addressed.Tarantino: HER3-DXd is an interesting and active ADC, including in patients who have received prior T-DXd. I feel there's going to be a lot more data [with this agent]. ADC sequencing is one of the most controversial and discussed topics in breast oncology because we're starting to have several ADCs. Finally, at ESMO Breast, we will have at least some data [in this area]. We need so much more, and there are large trials ongoing, but ESMO Breast will be one of the first conferences where there are some data in this setting.What early-phase data in triple-negative breast cancer might lead to paradigm-shifting advances?426RO - Pumitamig in Combination With DB-1305/BNT325 as First-Line (1L) Treatment for Patients With Advanced or Metastatic Triple-Negative Breast Cancer (a/mTNBC): Efficacy and Safety From a Multicenter, Open-Label, Phase 1/2 TrialPresentation time: May 8, 2026, 9:40-9:45 AM CESTSammons: We will also see exciting novel combination data in the triple-negative setting with a VEGF-targeted bispecific antibody called pumitamig [BNT327/BMS986545] given with a TROP2-directed ADC. The phase 1/2 data [NCT05438329] with pumitamig plus DB-1305/BNT325 appear to show an exciting overall response and disease-control rates for first-line metastatic TNBC [triple-negative breast cancer], where we still have a long way to go to improve outcomes.What research is evaluating the role of ovarian suppression in breast cancer?LBA2 - A Window-of-Opportunity (WOO) Trial of Giredestrant +/- LHRH Analogue vs Anastrozole + LHRHa in Premenopausal Patients With ER+/HER2- Early breast Cancer: PREcoopERAPresentation time: May 6, 2026, 5:02-5:12 PM CESTTolaney: I’m also looking forward to seeing data from the phase 2 PREcoopERA study [NCT05896566], which is trying to understand whether we need to use ovarian suppression when giving an oral selective estrogen receptor degrader. This has been a critical question, and it will be important to see [these results].ReferencesHarbeck N, Modi S, Pusztai L, et al. DESTINY-Breast11: neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC). Ann Oncol. 2025;36(suppl 2):S302-S303. doi:10.1016/j.annonc.2025.08.720Enhertu followed by THP supplemental biologics license application accepted in the US for patients with high-risk HER2-positive early-stage breast cancer prior to surgery. News release. Daiichi Sankyo. October 1, 2025. Accessed May 5, 2026. https://www.daiichisankyo.com/files/news/pressrelease/pdf/202510/20251001_E.pdf NewsletterStay up to date on the most recent and practice-changing oncology dataSubscribe Now! Advertisement Related ContentAdvertisementFDA Approves Zenocutuzumab for NRG1 Fusion+ Cholangiocarcinoma ByAshling Wahner May 8th 2026UT MD Anderson Shares Latest Research BreakthroughsByMD Anderson Cancer CenterMay 8th 2026Giants of Cancer Care Announces the 14th Annual Class of Inductees ByOncLiveMay 8th 2026OncLive Weekly News Quiz (5/8/2026): Test Your Knowledge on Key Breast, Lung, and Pancreatic Cancer UpdatesByOncLive StaffMay 8th 2026OncLive Polls Reveal Picks for Top Lung Cancer Abstracts at ASCO 2026ByCaroline SeymourMay 8th 2026 Latest CMEVideoProactive Adverse Event Management for HER2+ BTC TreatmentsRahul Gosain, MD, MBA; Rohit Gosain, MD; Rachna T. Shroff, MD, MS, FASCOView moreMultimediaCommunity Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for MelanomaYana G. Najjar, MD; Douglas B. Johnson, MD, MSCI; Rahul A. Sheth, MD, FSIR View moreVirtual EventWisconsin Association of Hematology and Oncology1 Session is Available!View moreVideoCommunity Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Empire State Hematology & Oncology SocietySeth A. Wander, MD, PhD; Girish Kunapareddy, MDView moreVirtual EventArkansas Association of Cancer Professionals2 Sessions are Available!View moreVideoCommunity Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | South Carolina Oncology SocietySeth A. Wander, MD, PhD; Kit Lu, MDView moreVideo19th Annual New York GU Cancers Congress®Maha Hussain, MD, FACP, FASCO; Daniel P. Petrylak, MDView moreIn-Person + Virtual EventGo to PER in ChicagoMay 29-31, 2026View moreVideoCommunity Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Tennessee Oncology Practice SocietySeth A. Wander, MD, PhD; Kamel Abou Hussein, MDView moreVirtual EventKansas Society of Clinical Oncology1 Session is Available!View moreVideoA Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)Cindy Neunert, MD, MSCS; Hanny Al-Samkari, MD; Joseph Shatzel, MD, MCRView moreVideoEvolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular TestingEileen M. O’Reilly, MD; E. Gabriela Chiorean, MD, FASCO; Michael J. Pishvaian, MD, PhD; Brian Wolpin, MD, MPHView moreVideoCases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple MyelomaC. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MDView moreVideoTumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLCBalazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MDView moreVideoMedical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic ApproachesRami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MDView moreVideoPER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging StrategiesJonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhDView moreVideoMedical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted TherapiesVinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen J. Bagley, MD, MSCE; Angela Waanders, MD, MPH, MSView moreVideoMedical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple MyelomaC. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MDView moreVideoMedical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 DysregulationRebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhDView moreVideoCases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical InsightsGail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHSView moreVideoMedical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast CancerWilliam J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhDView moreVideoGI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal CancerJohn H. Strickler, MD; Stacey A. Cohen, MD; Aparna Parikh, MD; Kanwal P.S. Raghav, MBBS, MDView moreVideoBreast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer TreatmentJoyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCOView moreMultimediaEstablishing the Rationale for ADC and ICI Combinations in TNBCVirginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCOView moreMultimediaBreaking Down the Rationale for Targeting TROP2 in TNBCFilipa Lynce, MD; Rita Nanda, MDView moreMultimediaDissecting Clinical Trial and Real-World Data for ADCs in TNBCFilipa Lynce, MD; Rita Nanda, MDView moreMultimediaEvaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBCAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MDView moreAudioBreaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLCRahul Gosain, MD, MBA; Rohit Gosain, MD; Hossein Borghaei, DO, MSView moreVideoOptimizing Treatment for Biliary Tract CancersGhassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhDView moreVideoCross-Disease Integration of Immunotherapy InnovationsGhassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhDView moreAudioPractical Considerations and Future Directions for New Treatment Strategies in SCLCRahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhDView moreMultimediaExpert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBCAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DScView moreVideoBroadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular CarcinomaGhassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhDView moreMultimediaPER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – NursingAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCOView moreMultimediaExpert Roundtable and Panel Discussions: Current and Future Landscape of TNBCAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCOView moreVideoShow Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast CancerAna C. Garrido-Castro, MD; Pedram Razavi, MD, PhDView moreAudioNavigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New OptionsRahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhDView moreVideoMedical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk AssessmentJason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MDView moreMultimediaReady for Radioligand Therapy? Patient Selection and Sequencing SimplifiedJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaWorking Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary CareJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaBURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate CancerJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaImaging Matters: Decoding PSMA PET for Better Decision-MakingJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaRadioligand Therapy 101: The Science Behind the StrategyJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCOView moreVideo Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease ContinuumTina Cascone, MD, PhD; Christina Baik, MD, MPH; David Planchard, MD, PhDView moreMultimediaCommunity Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary TeamYana G. Najjar, MD; Sapna Patel, MDView moreVideoA New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCsSandip Patel, MD, FASCO; Myung-Ju Ahn, MD; Giannis Mountzios, MD, MSc, PhD; Zofia Piotrowska, MD, MHSView moreVideoNavigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVOSriniVas R. Sadda, MD, FARVO; Mark R. Barakat, MD, FASRS; David A. Eichenbaum, MD, FASRSView moreVideoEnhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment StrategiesAna Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACPView moreVideo(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient OutcomesMichelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPOView more Advertisement Advertisement Trending on OncLive1Daraxonrasib Monotherapy Elicits Meaningful Responses in Previously Treated, RAS-Mutated Pancreatic Cancer2ASCO 2026 TNBC Deep Dive: Breast Cancer Experts Preview Practice-Informing Studies3Women With Bladder Cancer Face Diagnostic Delays as Symptoms Mimic UTIs, Experts Warn4Mentorship Is Key to Advance the Next Generation of Oncology Researchers5Dr Mauro on the Significance of Alternative TKI Formulations in CML